Tiziana Life Sciences (TLSA)
(Delayed Data from NSDQ)
$0.66 USD
+0.01 (1.80%)
Updated Apr 30, 2024 03:59 PM ET
After-Market: $0.67 +0.01 (2.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Tiziana Life Sciences Ltd [TLSA]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Foralumab Positive Exploratory COVID-19 Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Foralumab Trial Complete; Chief Medical Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Foralumab Clinical Progress; Modulating PT to $11 on Adjusted ADS Ratio
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Foralumab Patent Application Filed; ADS Ratio Change Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
StemPrintER Spinout Timing Clarity; Crucial New Patent Issuance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Grant Awarded in Alzheimer''s Disease; StemPrintER Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Tiziana Life Sciences Ltd
Industry: Medical - Biomedical and Genetics
Multiple Recent Clinical Catalysts; NASDAQ Listing Obtained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|